Mavyret addendum—ABBV’s new 2021 sales guidance of $1.9B (lowered from $2.0B) implies about $500M of Mavyret sales in 3Q21 and 4Q21. (1H21 Mavyret sales were $856M.)
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.